Mechanism: GLP-1 Mono-Agonism vs Triple Receptor Co-Agonism
Semaglutide and retatrutide both engage the GLP-1 receptor — but that is where the shared mechanism ends. Semaglutide is a selective GLP-1 receptor agonist with a C18 fatty diacid acylation producing a ~7-day half-life. Its entire pharmacological profile operates through GLP-1R: glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and hypothalamic satiety signalling.
Retatrutide (LY3437943) co-activates three receptors simultaneously: GLP-1R (appetite suppression, insulin secretion), GIPR (enhanced insulin sensitisation, adipocyte lipid metabolism), and Glucagon Receptor (GcgR: thermogenesis, hepatic fat oxidation, energy expenditure). GcgR agonism drives energy expenditure through thermogenic pathways that neither semaglutide nor tirzepatide engage.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Class | GLP-1 receptor agonist | Triple GLP-1/GIP/Glucagon agonist |
| Receptors | GLP-1R | GLP-1R + GIPR + GcgR |
| Half-life | ~7 days | ~6 days |
| Dosing interval | Once weekly | Once weekly |
| Energy expenditure | Moderate (GLP-1 only) | Higher (GcgR adds thermogenic component) |
| Phase of development | Phase 3 completed (multiple trials) | Phase 3 ongoing (TRIUMPH, 2026) |
Why glucagon receptor agonism matters GcgR activation increases hepatic fatty acid oxidation and thermogenesis — effectively raising metabolic rate. Combined with GLP-1R and GIPR agonism, this produces a synergistic energy deficit explaining retatrutide's superior Phase 2 weight loss outcomes.
Efficacy Comparison: What the Trial Data Shows
No direct head-to-head trial of retatrutide versus semaglutide has been published as of May 2026. The comparison below draws on separate trials with different populations, durations, and designs — cross-trial comparisons are hypothesis-generating, not definitive.
| Compound | Trial | Duration | Max dose | Mean weight loss |
|---|---|---|---|---|
| Semaglutide | STEP 1 (NEJM 2021) | 68 weeks | 2.4mg/week | 14.9% |
| Retatrutide | Phase 2 (NEJM 2023) | 24 weeks | 8mg/week | 19.2% |
| Retatrutide | Phase 2 (NEJM 2023) | 48 weeks | 12mg/week | 24.2% |
The 24.2% mean body weight reduction in the 12mg retatrutide cohort is the highest weight loss outcome reported for any GLP-1 class compound in a controlled trial as of 2026. For comparison: tirzepatide SURMOUNT-1 reported 20.9% at 15mg over 72 weeks; semaglutide STEP 1 reported 14.9% at 2.4mg over 68 weeks.
Caveats: STEP 1 ran for 68 weeks vs Phase 2 retatrutide at 48 weeks; baseline populations differed; placebo-subtracted drug effects are smaller than unadjusted means. The magnitude of difference (14.9% vs 24.2%) remains substantial relative to methodological noise.
For the full three-compound comparison including tirzepatide, see the GLP-1 Peptides Comparison Guide. For lean mass data, see GLP-1 and Lean Mass Loss.
Side Effect Profile Comparison
Both compounds produce a GI-dominant adverse event profile. Key differences are in severity and discontinuation rate:
| Adverse event | Semaglutide 2.4mg (STEP 1) | Retatrutide 12mg (Phase 2) |
|---|---|---|
| Nausea | 44% | ~65% |
| Vomiting | 25% | ~35% |
| Diarrhoea | 30% | ~42% |
| Constipation | 24% | ~26% |
| Discontinuation due to AEs | ~7% | ~16% |
Semaglutide's lower AE burden reflects single-receptor targeting. Its long-term safety advantage: completed cardiovascular outcomes data (SELECT trial, 2023 — 20% MACE reduction in non-diabetic obesity). Retatrutide's cardiovascular outcomes trial (SYNERGY-OUTCOMES) is ongoing as of 2026.
For the full retatrutide AE profile, see Retatrutide Side Effects: Phase 2 Safety Data. For the semaglutide safety review, see Semaglutide Research Guide.
Research Considerations: Which Compound to Choose
Semaglutide and retatrutide suit different research objectives:
| Research objective | Recommended | Rationale |
|---|---|---|
| Maximum weight loss endpoint | Retatrutide (8mg or 12mg) | 24.2% vs 14.9% mean body weight reduction |
| Established long-term safety | Semaglutide | Multiple completed Phase 3 trials — deepest evidence base in class |
| Cardiovascular outcomes research | Semaglutide | SELECT trial completed (20% MACE reduction). Retatrutide outcomes trial ongoing |
| Thermogenic / energy expenditure research | Retatrutide | GcgR co-agonism adds thermogenic pathway absent from semaglutide |
| Lower GI AE burden | Semaglutide | Lower nausea/vomiting rates and lower discontinuation risk |
Both compounds are available research-grade from RetaLABS with COA-backed quality assurance and Express Post shipping across Australia. See Retatrutide and Semaglutide for current stock and pricing.